Compare Avantis US Small Cap Value ETF (AVUV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Merck & Co., Inc. — how do they compare? Avantis US Small Cap Value ETF trades at $128.01, while Merck & Co., Inc. trades at $133.26 (market cap $327.94B). The key difference: Merck & Co., Inc. pays a 2.56% dividend while Avantis US Small Cap Value ETF pays none. Which is the better fit depends on your goals.
| AVUV | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $128.74 | $132.93 |
52-Week Low | $93.93 | $77.60 |
Market Cap | — | $327.94B |
Enterprise Value | — | $374.70B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV, a U.S. small-cap value ETF, trades at $127.51, up 0.4% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights its strong 2026 performance, outpacing the Russell 2000, and positioning it as a diversification tool for tech-heavy portfolios. The fund benefits from a shift toward value stocks and potential rate cut tailwinds.
The outlook for AVUV is positive, driven by small-cap value momentum and investor rotation away from large-cap concentration. Key risks include sensitivity to interest rates, regional bank exposure, and higher small-cap volatility. Analyst sentiment is optimistic, with media coverage emphasizing its role in balanced long-term strategies.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01B in 2025, and net income reached $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples and competitive pressures. Analysts maintain a bullish consensus with a $140.58 price target, suggesting potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
